Fast Market Research

New Market Report: Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022

New Pharmaceuticals market report from GlobalData: "Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022"


Boston, MA -- (SBWIRE) -- 08/01/2012 -- GlobalData's pharmaceuticals report, "Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022" provides Namenda global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

View Full Report Details and Table of Contents


- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Namenda including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Namenda including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2002-2022 for Namenda

Reasons to Get this Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022
- LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022
- Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022
- Aricept (Alzheimer's disease) - Analysis and Forecasts to 2022
- Exelon (Alzheimer's disease) - Analysis and Forecasts to 2022
- Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
- Eliquis (Atrial Fibrillation) - Analysis and Forecasts to 2022
- Forest Laboratories, Inc. (FRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Brinavess (Atrial Fibrillation) - Analysis and Forecasts to 2022
- Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022